Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00887432 · ClinicalTrials.gov registry record · NA

Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation

A NA study of Prostate Adenocarcinoma, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
NA
Development phase
132
Enrollment target
1
Study location

NCT00887432: Completed NA study of Prostate Adenocarcinoma, sponsored by Roswell Park Cancer Institute.

NCT00887432 is a NA study of Prostate Adenocarcinoma that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 132 participants, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00887432, a NA study of Prostate Adenocarcinoma, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
NA
Development phase
132 participants
Enrollment target
1
Study location

Study Summary

This randomized clinical trial studies how well cholecalciferol supplement works in treating patients with localized prostate cancer undergoing observation. Cholecalciferol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly.

Primary Outcome

Difference in the mean change in PSA on vitamin D (9 month period: pre-Vitamin D to 9 months after start of vitamin D) versus on placebo (9 month period: pre-Placebo to 9 months after starting placebo). Compared using a paired t-test.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Cholecalciferol
  • OTHER Quality-of-Life Assessment
  • OTHER Laboratory Biomarker Analysis
  • DRUG Placebo Administration
  • OTHER Patient Observation

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2009-04-08
Est. Completion 2020-06-08
Phase NA
Roswell Park Cancer Institute

365 total trials

What the finished NCT00887432 record still lists

NCT00887432 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (39% lower).

The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Cholecalciferol is the first listed.

NCT00887432 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00887432 about?

NCT00887432 is a clinical study titled "Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation". This randomized clinical trial studies how well cholecalciferol supplement works in treating patients with localized prostate cancer undergoing observation. Cholecalciferol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly.

What is the current status of trial NCT00887432?

This trial is currently completed. It is a NA study. The enrollment target is 132 participants. The study started on 2009-04-08. Estimated completion is 2020-06-08.

What conditions does trial NCT00887432 study?

This clinical trial studies the following conditions: Prostate Adenocarcinoma.

What interventions are being tested in trial NCT00887432?

The interventions under investigation include: Cholecalciferol (DIETARY_SUPPLEMENT), Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Placebo Administration (DRUG), Patient Observation (OTHER).

Who is sponsoring clinical trial NCT00887432?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00887432 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00887432's enrollment target sits among peer trials

132 31st of 99 higher than 69 of 99 other Prostate Adenocarcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01766297 · 132 participants · Phase 2

    Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

  • NCT04002947 · 132 participants · Phase 2

    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  • NCT04128189 · 132 participants · Phase 3

    Shingrix in Renal Transplant Recipients

  • NCT04199780 · 132 participants · NA

    Effects of tDCS Combined With CBI on Postsurgical Pain

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00887432, the US trial registry maintained by the National Library of Medicine. NCT00887432 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.